Press release
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June ...
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2
About this update from Meiragtx Holdings Plc
[{"type":"text","content":"MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023 \n LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company’s AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on Tuesday, June 27, 2023, at 8:00 a.m. ET. The presentation will include: 1) Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQP1 in the unilateral and bilateral cohorts: Safety and tolerability12-month data for PRO assessments of xerostomia symptoms in the unilateral cohorts (n=12)12-month data for PRO assessments of xerostomia symptoms in the bilateral cohorts (n=12)Change over time in the objective measure of saliva flow out to 12 months for both bilateral and unilateral cohortsLong-term follow up data to 2 or 3 years for the participants who have reached those timepoints 2) Summary of biopsy data from a subset of patients in the Phase 1 National Institutes of Health (NIH) study of AAV-hAQP1 in RIX demonstrating parotid transduction and durability out to at least 24-months post-treatment. 3) Overview of the recently initiated randomized, double blind, placebo-controlled Phase 2 study of AAV-hAQP1 for the treatment of RIX, now enrolling patients. A question-and-answer session will follow the formal presentation. To register and attend the event, please click here. A live webcast of the call, as well as a replay, will be available on the Investors page of the Company’s website at www.investors.meiragtx.com/. About the Phase 1 AQUAx Clinical Trial The Phase 1 AQUAx clinical trial is an open-label, non-randomized, dose escalation trial designed to evaluate the safety of MeiraGTx’s investigational gene therapy AAV-hAQP1 when administered via Stensen's duct to one or both parotid glands in patients who have been diagnosed with grade 2 or 3 radiation-induced xerostomia and who have remained cancer free for at least five years (or at least two years if HPV+) after receiving radiation treatment ...